eGene Adds Sales Director to Staff to Move Sales to Next Level
IRVINE, Calif., May 24, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), a leading bioengineering company that has developed a compact and automated digital genetic analyzer, today announced that David Molnar has joined eGene as director of sales.
Molnar brings an extensive background in general sales management in the U.S. and Asia to the company. In his previous positions he has been responsible for adding $10 million to bottom-line profits in one year; leading growth of North American sales from $20 to $40 million in a three-year period and has negotiated multi-product, long-term agreements with major corporations.
"We are very excited to add David to our team," said Dr. Ming Liu, acting CEO of eGene Inc. "David brings a proven ability to generate significant sales, which is something that we have made a priority for 2006. I believe that his efforts will help increase eGene's visibility and revenues in the future."
Prior to joining eGene, Molnar was national sales manager of Matsuo Electronic of America Inc. (subsidiary of Matsuo Electric Co. Ltd., Japan) where he was responsible for revamping pricing structures to turnaround sales from 0% profit to a 15% profit in an industry where the average was 5-6%. Before that he was senior sales representative at Fisher Scientific Co. (previously Curtin Matheson) where he achieved top-10 sales ranking out of 300 sales reps, receiving numerous supplier and company awards for excellent performance. Prior to that affiliation he was sales manager at LabMart where he drove sales from 0 to $10 million, surpassing sales goals by 30%. His first position was as a sales representative at Curtin Matheson Sci. Co., where he was responsible for sales of high-technology equipment and chemicals to biotech, clinical lab, hospital and research facilities. He spearheaded the development of a non-producing territory to the No. 1 producer in the branch, consistently surpassing sales goals by 10-20% during the 11 years he was with the company.
He holds a Bachelor of Science degree from Findlay College in Findlay, Ohio.
eGene ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
The company has developed the HDA-GT12 (high-performance DNA analyzer for genotyping on 12 channels) which is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
Copyright Business Wire 2006
